These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 22687648)

  • 1. Tenascin-C in human cardiac pathology.
    Niebroj-Dobosz I
    Clin Chim Acta; 2012 Oct; 413(19-20):1516-8. PubMed ID: 22687648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating tenascin-C levels in patients with dilated cardiomyopathy in the course of Emery-Dreifuss muscular dystrophy.
    Niebroj-Dobosz I; Madej-Pilarczyk A; Marchel M; Sokołowska B; Hausmanowa-Petrusewicz I
    Clin Chim Acta; 2011 Aug; 412(17-18):1533-8. PubMed ID: 21596026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction.
    Sato A; Aonuma K; Imanaka-Yoshida K; Yoshida T; Isobe M; Kawase D; Kinoshita N; Yazaki Y; Hiroe M
    J Am Coll Cardiol; 2006 Jun; 47(11):2319-25. PubMed ID: 16750702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, B⁺ tenascin-C and ED-A⁺ fibronectin in dilated cardiomyopathy: potential impact on disease progression and patients' prognosis.
    Franz M; Berndt A; Neri D; Galler K; Grün K; Porrmann C; Reinbothe F; Mall G; Schlattmann P; Renner A; Figulla HR; Jung C; Küthe F
    Int J Cardiol; 2013 Oct; 168(6):5344-51. PubMed ID: 23998545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tenascin-C in cardiac disease: a sophisticated controller of inflammation, repair, and fibrosis.
    Imanaka-Yoshida K; Tawara I; Yoshida T
    Am J Physiol Cell Physiol; 2020 Nov; 319(5):C781-C796. PubMed ID: 32845719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incremental prognostic values of serum tenascin-C levels with blood B-type natriuretic peptide testing at discharge in patients with dilated cardiomyopathy and decompensated heart failure.
    Fujimoto N; Onishi K; Sato A; Terasaki F; Tsukada B; Nozato T; Yamada T; Imanaka-Yoshida K; Yoshida T; Ito M; Hiroe M
    J Card Fail; 2009 Dec; 15(10):898-905. PubMed ID: 19944367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of serum tenascin-C levels on long-term outcome after acute myocardial infarction.
    Sato A; Hiroe M; Akiyama D; Hikita H; Nozato T; Hoshi T; Kimura T; Wang Z; Sakai S; Imanaka-Yoshida K; Yoshida T; Aonuma K
    J Card Fail; 2012 Jun; 18(6):480-6. PubMed ID: 22633306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High prevalence of chronic myocarditis in dilated cardiomyopathy referred for left ventriculoplasty: expression of tenascin C as a possible marker for inflammation.
    Tsukada B; Terasaki F; Shimomura H; Otsuka K; Otsuka K; Katashima T; Fujita S; Imanaka-Yoshida K; Yoshida T; Hiroe M; Kitaura Y
    Hum Pathol; 2009 Jul; 40(7):1015-22. PubMed ID: 19297005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher serum tenascin-C levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardiomyopathy.
    Terasaki F; Okamoto H; Onishi K; Sato A; Shimomura H; Tsukada B; Imanaka-Yoshida K; Hiroe M; Yoshida T; Kitaura Y; Kitabatake A;
    Circ J; 2007 Mar; 71(3):327-30. PubMed ID: 17322629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tenascin-C levels in patients with idiopathic dilated cardiomyopathy.
    Aso N; Tamura A; Nasu M
    Am J Cardiol; 2004 Dec; 94(11):1468-70. PubMed ID: 15566931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum tenascin-C as a potential predictive marker of angiogenesis in non-small cell lung cancer.
    Ishiwata T; Takahashi K; Shimanuki Y; Ohashi R; Cui R; Takahashi F; Shimizu K; Miura K; Fukuchi Y
    Anticancer Res; 2005; 25(1B):489-95. PubMed ID: 15816617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac extracellular matrix tenascin-C deposition during fibronectin degradation.
    Ma S; Yang D; Li D; Tang B; Sun M; Yang Y
    Biochem Biophys Res Commun; 2011 Jun; 409(2):321-7. PubMed ID: 21586275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corneal wound healing in tenascin knockout mouse.
    Matsuda A; Yoshiki A; Tagawa Y; Matsuda H; Kusakabe M
    Invest Ophthalmol Vis Sci; 1999 May; 40(6):1071-80. PubMed ID: 10235540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling.
    Jones FS; Jones PL
    Dev Dyn; 2000 Jun; 218(2):235-59. PubMed ID: 10842355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury.
    Tamaoki M; Imanaka-Yoshida K; Yokoyama K; Nishioka T; Inada H; Hiroe M; Sakakura T; Yoshida T
    Am J Pathol; 2005 Jul; 167(1):71-80. PubMed ID: 15972953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic utility of tenascin-C for evaluation of the activity of human acute myocarditis.
    Morimoto S; Imanaka-Yoshida K; Hiramitsu S; Kato S; Ohtsuki M; Uemura A; Kato Y; Nishikawa T; Toyozaki T; Hishida H; Yoshida T; Hiroe M
    J Pathol; 2005 Mar; 205(4):460-7. PubMed ID: 15685595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The interaction of tenascin-C with fibronectin modulates the migration and specific metalloprotease activity in human mesothelioma cell lines of different histotype.
    Giuffrida A; Scarpa S; Birarelli P; Modesti A
    Int J Oncol; 2004 Sep; 25(3):745-50. PubMed ID: 15289878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of tenascin-C on normal and diabetic retinal endothelial cells in culture.
    Castellon R; Caballero S; Hamdi HK; Atilano SR; Aoki AM; Tarnuzzer RW; Kenney MC; Grant MB; Ljubimov AV
    Invest Ophthalmol Vis Sci; 2002 Aug; 43(8):2758-66. PubMed ID: 12147613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matricellular proteins in the heart: possible role during stress and remodeling.
    Schellings MW; Pinto YM; Heymans S
    Cardiovasc Res; 2004 Oct; 64(1):24-31. PubMed ID: 15364610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased expression of syndecan-1 protects against cardiac dilatation and dysfunction after myocardial infarction.
    Vanhoutte D; Schellings MW; Götte M; Swinnen M; Herias V; Wild MK; Vestweber D; Chorianopoulos E; Cortés V; Rigotti A; Stepp MA; Van de Werf F; Carmeliet P; Pinto YM; Heymans S
    Circulation; 2007 Jan; 115(4):475-82. PubMed ID: 17242279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.